

Neutropenia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/NA77E2B7D40AEN.html>

Date: June 2022

Pages: 102

Price: US\$ 2,000.00 (Single User License)

ID: NA77E2B7D40AEN

Abstracts

Neutropenia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neutropenia – Drugs In Development, 2022, provides an overview of the Neutropenia (Hematological Disorders) pipeline landscape.

Neutropenia is an abnormally low count of neutrophils, a type of white blood cell that helps fight off infections, particularly those caused by bacteria and fungi. Signs and symptoms include fevers, frequent infections, mouth ulcers, gum infections and dysuria.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neutropenia – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Neutropenia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neutropenia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Neutropenia and features dormant and

discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 3, 2, 7, 6 and 13 respectively.

Neutropenia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Neutropenia (Hematological Disorders).

The pipeline guide reviews pipeline therapeutics for Neutropenia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Neutropenia (Hematological Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Neutropenia (Hematological Disorders)

therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Neutropenia (Hematological Disorders)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Neutropenia (Hematological Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Neutropenia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Neutropenia – Overview

Neutropenia – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Neutropenia – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Neutropenia – Companies Involved in Therapeutics Development

Neutropenia – Drug Profiles

Neutropenia – Dormant Projects

Neutropenia – Discontinued Products

Neutropenia – Product Development Milestones

Featured News & Press Releases

Mar 29, 2022: EMA recommends granting a marketing authorisation for stimufend

Dec 08, 2021: Emendo Biotherapeutics to present new data at 63rd ASH Annual Meeting & Exhibition

Dec 02, 2021: X4 Pharmaceuticals to host virtual seminar “Understanding Primary Immunodeficiencies” to highlight broadening market opportunities for mavorixafor

Aug 03, 2021: X4 Pharmaceuticals announces key enrollment milestone achievements in ongoing mavorixafor clinical trials and reports second quarter financial results

Oct 12, 2020: BeyondSpring forms partnership advisory committee comprised of industry veterans

Sep 29, 2020: JAMA Oncology highlights plinabulin's efficacy in preventing chemotherapy-induced neutropenia as a monotherapy

May 27, 2020: FDA accepts for review Fresenius Kabi's first biosimilar regulatory submission for MSB11455, a biosimilar candidate of pegfilgrastim

May 22, 2020: Fresenius Kabi's regulatory submission for pegfilgrastim biosimilar accepted for review by EMA

Apr 28, 2020: Mylan and Biocon launch Fulphila, Biosimilar Pegfilgrastim, in Canada

Apr 14, 2020: Biocon and Mylan Launch Fulphila, Biosimilar Pegfilgrastim, in Australia

Nov 05, 2019: X4 Pharmaceuticals initiates phase 1b clinical trial of Mavorixafor for the treatment of severe Congenital Neutropenia

Sep 23, 2019: BeyondSpring's Plinabulin continues to build on superior product profile in breast cancer trial for neutropenia prevention

Aug 23, 2019: BeyondSpring plinabulin demonstrates superior quality of life over pegfilgrastim in a head-to-head comparison trial for the prevention of neutropenia

May 20, 2019: BeyondSpring abstract demonstrating bone pain benefit with lead asset, Plinabulin, versus Neulasta for neutropenia prevention Presented at ISPOR 2019

May 16, 2019: BeyondSpring's rationale for the plinabulin-neulasta combination for neutropenia prevention accepted as abstracts at 2019 ASCO Annual Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Neutropenia, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Neutropenia – Pipeline by Akthelia Pharmaceuticals Ltd, 2022
Neutropenia – Pipeline by Aprilbio Co Ltd, 2022
Neutropenia – Pipeline by BeyondSpring Inc, 2022
Neutropenia – Pipeline by Biocon Ltd, 2022
Neutropenia – Pipeline by Biocure Technology Inc, 2022
Neutropenia – Pipeline by Biosidus SA, 2022
Neutropenia – Pipeline by Biosimilar Solutions LLC, 2022
Neutropenia – Pipeline by Cellerant Therapeutics Inc, 2022
Neutropenia – Pipeline by CPL Biologicals Pvt Ltd, 2022
Neutropenia – Pipeline by CSPC Pharmaceutical Group Ltd, 2022
Neutropenia – Pipeline by Dr. Reddy's Laboratories Ltd, 2022
Neutropenia – Pipeline by EmendoBio Inc, 2022
Neutropenia – Pipeline by Genova Biotech Company Ltd, 2022
Neutropenia – Pipeline by Ilkogen Ilac San Ve Tic AS, 2022
Neutropenia – Pipeline by InflaRx NV, 2022
Neutropenia – Pipeline by Lupin Ltd, 2022
Neutropenia – Pipeline by Merck & Co Inc, 2022
Neutropenia – Pipeline by Mycenax Biotech Inc, 2022
Neutropenia – Pipeline by Phoenicia Biosciences Inc, 2022
Neutropenia – Pipeline by Prolong Pharmaceuticals LLC, 2022
Neutropenia – Pipeline by Qilu Pharmaceutical Co Ltd, 2022
Neutropenia – Pipeline by Seres Therapeutics Inc, 2022
Neutropenia – Pipeline by Shenzhen Xinpeng Bio-technology Co Ltd, 2022
Neutropenia – Pipeline by Siam Bioscience Co Ltd, 2022
Neutropenia – Pipeline by Statera Biopharma Inc, 2022
Neutropenia – Pipeline by Tanvex BioPharma Inc, 2022
Neutropenia – Pipeline by Toko Pharmaceutical Industries Co Ltd, 2022

Neutropenia – Pipeline by USV Pvt Ltd, 2022
Neutropenia – Pipeline by X4 Pharmaceuticals Inc, 2022
Neutropenia – Dormant Projects, 2022
Neutropenia – Dormant Projects, 2022 (Contd..1)
Neutropenia – Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

- Number of Products under Development for Neutropenia, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022

I would like to order

Product name: Neutropenia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/NA77E2B7D40AEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/NA77E2B7D40AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

